Syntara Drug Slows Motor Decline in Early Parkinson’s Risk Group, Placebo Worsens [VIDEO]
Syntara SNT-4728 Parkinson's Phase 2 results show a statistically significant motor improvement (p=0.021) that held 12 weeks after dosing, backing up earlier evidence of reduced brain inflammation.
Key Takeaways
- SNT-4728 beat placebo on clinician-assessed motor signs at Week 24 (p=0.021, MDS-UPDRS Part III), 12 weeks after treatment ended.
- The result is the second positive readout in the study, following the 6 July 2026 TSPO PET finding (p=0.0145) with 67% of participants showing reduced putamen inflammation.
- The SNT-4728 group improved while placebo deteriorated, and no treatment-related serious adverse events were reported in the 41-participant, 3:1 randomised study.
- The smartphone motor composite was directionally consistent but not statistically significant, and other measures including MoCA, SF-36 and RBDQ showed no marked change.
- No new trial, timeline or funding was announced, so the next catalyst is a further study design after Professor Lewis presents in Seoul on 7 October 2026.
This is a special feature video produced for our partner.